.Attributes Medication, Released online: thirteen September 2024 doi:10.1038/ s41591-024-03261-7In the non-randomized stage 3b/4 DESTINY-Breast12 research study, trastuzumab deruxtecan (T-DXd) therapy of individuals with HER2+ enhanced bosom cancer as well as active or even dependable mind metastases showed steady intracranial task and also wide spread efficiency of T-DXd.